ERBB2 and breast cancer: In the HALT-D study of crofelemer for the prevention of CID in patients with HER2-positive BC receiving PH and a taxane, there was no significant difference in the number of patients experiencing ≥ 2 consecutive days of diarrhea between the crofelemer and control arms.